Prenatal THC and Primate Muscle Research: Gene Changes Are Not a Clinical Diagnosis
A pilot study found altered gene expression in muscle from THC-exposed primate offspring, with relatively narrow overall developmental effects. Its findings warrant further research, but they do not establish a diagnosed muscle disorder in human children or a method for attributing an individual child’s condition to cannabis.
The exposure and tissue studied
Moellmer and colleagues studied rhesus macaques assigned to THC exposure or control conditions. THC was administered orally through research edibles, with dosing established before breeding and maintained through the relevant offspring time points. Offspring were studied in separate fetal and infant cohorts.
The investigators examined rectus femoris skeletal muscle. They evaluated tissue morphology and used a gene-expression panel emphasizing neuroinflammatory pathways. The specimen was muscle tissue, not a human blood or urine drug test.
What the molecular findings mean
Differentially expressed genes and pathway analyses pointed particularly toward inflammation and cytokine signaling. Those observations identify biological responses and hypotheses about possible consequences. They do not, by themselves, establish that the offspring had a clinically important loss of strength, a permanent disability, or the same outcome a human patient might experience.
The authors describe the overall effects on muscle development as narrow and frame the work as a pilot establishing feasibility for longer-term and functional investigation. That qualification belongs alongside the positive molecular findings.
Why the experimental details limit translation
Small cohorts, separate developmental sampling points, and a targeted molecular panel restrict the conclusions. Gene-expression differences depend on tissue and timing; they are not interchangeable with protein activity or measured muscle performance. The standardized animal exposure also differs from many human product, dose, and route histories.
Because exposure began before pregnancy and continued through the study’s relevant period, the design should not be described as isolating a single brief exposure at one precise gestational stage.
Questions for an individual causation opinion
Ask whether the claimed injury matches an outcome actually measured, whether the species and exposure differences have been addressed, and whether there is human evidence connecting the proposed mechanism to the specific condition. A pathway associated with inflammation is not a diagnosis of inflammation-related disability.
The study supplies mechanistic developmental evidence. Individual attribution still requires reliable exposure history, clinical findings, timing, and consideration of other causes.
Related evidence
For the distinction between detecting cannabis and establishing its significance, see our analysis of exposure, impairment, and crash-risk evidence.
Primary research
Effects of in utero delta-9-tetrahydrocannabinol (THC) exposure on fetal and infant musculoskeletal development in a preclinical nonhuman primate model. PLOS ONE, 2024. DOI: 10.1371/journal.pone.0306868.
